Sodium iodide i 131
Hicon (sodium iodide i 131) is a small molecule pharmaceutical. Sodium iodide i 131 was first approved as Sodium iodide i 131 on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Hicon (generic drugs available since 2020-02-05)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| colloidal iodine solution | unapproved drug other | 2023-05-23 |
| hicon | New Drug Application | 2022-03-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
V: Various drug classes in atc
— V09: Diagnostic radiopharmaceuticals
— V09F: Thyroid diagnostic radiopharmaceuticals
— V09FX: Various thyroid diagnostic radiopharmaceuticals
— V09FX03: Sodium iodide (131i)
— V10: Therapeutic radiopharmaceuticals
— V10X: Other therapeutic radiopharmaceuticals in atc
— V10XA: Iodine (131i) compounds
— V10XA01: Sodium iodide (131i)
HCPCS
No data
Clinical
Clinical Trials
183 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | 12 | 14 | 3 | — | 8 | 35 | |
| Non-hodgkin lymphoma | D008228 | C85.9 | 7 | 14 | 3 | — | 2 | 25 | |
| Thyroid neoplasms | D013964 | EFO_0003841 | 2 | 9 | 6 | — | 6 | 21 | |
| Lymphoma | D008223 | C85.9 | 2 | 4 | 1 | — | — | 7 | |
| Follicular lymphoma | D008224 | C82 | 1 | 3 | 1 | — | — | 5 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | 3 | — | 1 | 5 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | 1 | 1 | — | 1 | 4 |
| Ganglioneuroblastoma | D018305 | 1 | — | 1 | — | — | 2 | ||
| Adrenal gland neoplasms | D000310 | EFO_0003850 | C74 | — | — | 1 | — | — | 1 |
| Adrenal gland diseases | D000307 | HP_0000834 | E27.9 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pheochromocytoma | D010673 | 3 | 4 | — | — | 7 | 13 | ||
| Central nervous system neoplasms | D016543 | 7 | 4 | — | — | 2 | 11 | ||
| Neoplasms | D009369 | C80 | 7 | 6 | — | — | — | 10 | |
| Paraganglioma | D010235 | 3 | 3 | — | — | 4 | 9 | ||
| Melanoma | D008545 | 5 | 2 | — | — | — | 6 | ||
| Glioblastoma | D005909 | EFO_0000515 | 4 | 4 | — | — | — | 6 | |
| Prostatic neoplasms | D011471 | C61 | 3 | 2 | — | — | — | 5 | |
| Multiple myeloma | D009101 | C90.0 | 3 | 3 | — | — | — | 5 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 2 | 3 | — | — | — | 5 | |
| Mantle-cell lymphoma | D020522 | C83.1 | 1 | 4 | — | — | — | 5 |
Show 36 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 7 | — | — | — | — | 7 | ||
| Head and neck neoplasms | D006258 | 2 | — | — | — | 1 | 3 | ||
| Non-small-cell lung carcinoma | D002289 | 3 | — | — | — | — | 3 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | — | — | — | — | 3 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Digestive system neoplasms | D004067 | 1 | — | — | — | — | 1 | ||
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
| Respiratory tract neoplasms | D012142 | EFO_0003853 | D14 | 1 | — | — | — | — | 1 |
| Connective and soft tissue neoplasms | D018204 | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graves disease | D006111 | EFO_0004237 | E05.0 | — | — | — | — | 1 | 1 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | — | — | 1 | 1 | |
| Hyperthyroidism | D006980 | E05.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SODIUM IODIDE I 131 |
| INN | sodium iodide (131i) |
| Description | Hicon (sodium iodide i 131) is a small molecule pharmaceutical. Sodium iodide i 131 was first approved as Sodium iodide i 131 on 1982-01-01. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | [131I-].[Na+] |
Identifiers
| PDB | — |
| CAS-ID | 7790-26-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201084 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 29VCO8ACHH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,978 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
6,705 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more